益佰制药(600594) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was CNY 657,132,885, representing a year-over-year increase of 0.61%[4] - The net profit attributable to shareholders for Q3 2023 was CNY 41,963,911.92, a decrease of 39.32% compared to the same period last year[4] - The basic earnings per share for Q3 2023 was CNY 0.053, down 39.08% year-over-year[5] - The net profit attributable to shareholders for the year-to-date was CNY 169,869,961.21, down 13.33% compared to the same period last year[4] - The company reported a decrease of 7.64% in net profit after deducting non-recurring gains and losses for the year-to-date, totaling CNY 142,946,602.53[4] - The net profit for Q3 2023 was CNY 161,499,907.31, a decrease of 16.8% compared to CNY 194,249,563.62 in Q3 2022[21] - The total profit for Q3 2023 was CNY 194,907,546.17, down from CNY 239,833,220.77 in the same period last year, representing a decline of 18.7%[21] - The basic and diluted earnings per share for Q3 2023 were CNY 0.215, compared to CNY 0.247 in Q3 2022, reflecting a decrease of 13.0%[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,901,384,082.50, reflecting a slight increase of 0.73% from the end of the previous year[5] - As of September 30, 2023, the company's total current assets amounted to RMB 2,137,225,252.45, an increase from RMB 2,040,631,267.51 at the end of 2022, reflecting a growth of approximately 4.8%[16] - The total equity attributable to shareholders at the end of the reporting period was CNY 3,214,168,065.93, an increase of 5.58% from the previous year-end[5] - The company's total assets as of the end of the third quarter of 2023 amounted to ¥4,901,384,082.50, compared to ¥4,865,807,509.44 at the end of the same period in 2022, showing an increase of about 0.7%[18] - Total liabilities decreased to ¥1,549,886,283.75 in 2023 from ¥1,675,881,347.56 in 2022, representing a decline of approximately 7.5%[18] - The total non-current assets increased to CNY 2,829,498,234.86, reflecting an adjustment of CNY 4,321,992.93[31] - Current liabilities totaled CNY 1,172,715,463.95, remaining stable compared to previous periods[32] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was CNY 343,155,292.85, showing an increase of 10.88%[5] - The cash flow from investing activities for the first nine months of 2023 was negative CNY 102,439,355.09, an improvement from negative CNY 247,113,792.77 in the same period of 2022[26] - Cash and cash equivalents at the end of Q3 2023 totaled CNY 683,933,062.18, down from CNY 900,905,459.29 at the end of Q3 2022, indicating a decrease of 24.1%[27] Shareholder Information - The top shareholder, Dou Qiling, holds 185,457,636 shares, representing 23.42% of the total shares[14] - The second-largest shareholder, Zhang Biling, holds 20,971,344 shares, accounting for 2.65% of the total shares[14] - The company has not disclosed any related party relationships among the top ten shareholders[14] Government Support and Non-Recurring Gains - The company received government subsidies amounting to CNY 6,024,954.46 during the reporting period, contributing to its non-recurring gains[7] Future Outlook and Strategic Initiatives - The company has not provided any specific guidance for future performance or new product developments in the current report[16] - The company plans to continue focusing on market expansion and new product development as part of its strategic initiatives moving forward[20] - The company is focused on enhancing its financial position and exploring new strategies for market expansion and product development[34] Operating Costs and Expenses - Total operating costs for the first three quarters of 2023 were ¥1,930,208,223.55, compared to ¥1,901,760,985.35 in 2022, indicating an increase of about 1.5%[20] - The company incurred operating expenses of CNY 2,002,763,789.31 in Q3 2023, compared to CNY 1,939,622,241.77 in Q3 2022, reflecting an increase of 3.2%[26] - Research and development expenses decreased to ¥73,852,804.23 in 2023 from ¥78,838,392.66 in 2022, reflecting a reduction of approximately 6.3%[20] - The company reported a decrease in financial expenses to ¥11,084,045.56 in 2023 from ¥24,737,766.33 in 2022, indicating a reduction of approximately 55.2%[20]